Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online meetings and deadlines has, of course, returned. You knew this would happen, though, yes? After all, the world is round and keeps spinning, notwithstanding conspiracy theories. So to cope, we are brewing a cup or three of stimulation. Our choice today is the delicious cinnamon mocha. Please feel free to join us. Meanwhile, here are some tidbits. Hope your day goes well, and do stay in touch. …

AstraZeneca (AZN) chief executive officer Pascal Soriot is at the center of an extraordinary row among investors over his multi-million-dollar bonus, This is Money reports. Major shareholders are locked in heated talks after the drug maker proposed boosting his bonus and performance-related share award by $3.25 million to $17 million. The plan could take his overall pay above the $21.8 million he received last year. Two top shareholders, Aviva Investors and Standard Life Aberdeen, already voted to block the proposal ahead of the annual meeting on Tuesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.